Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Small interfering RNA targeting Hspb1 is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the Hspb1 gene (also known as Heat Shock Protein 27 or HSP27). Hspb1 is a molecular chaperone that plays a critical role in protecting cells from stress and acts as a negative regulator of ferroptosis, an iron-dependent form of regulated cell death. In the context of hepatocellular carcinoma (HCC), Hspb1 is often upregulated and contributes to treatment resistance. By utilizing siRNA to downregulate Hspb1, researchers aim to trigger ferroptosis, disrupt lipid metabolism, and sensitize tumors to radiotherapy and immune checkpoint inhibitors (such as anti-PD-1 therapy). Preclinical studies indicate that this approach not only directly inhibits tumor growth but also promotes a more robust anti-tumor immune response by increasing the infiltration of cytotoxic CD8+ T cells into the tumor microenvironment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hspb1 siRNA.